Study of BMS-354825 (Dasatinib) in Patients With Chronic Myeloid Leukemia Who Are Either Resistant or Intolerant to Imatinib

NCT00101660 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

387

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Myeloid Leukemia
Philadelphia-Positive Myeloid Leukemia

Interventions

DRUG: Dasatinib

Sponsor

Bristol-Myers Squibb